Pfizer Inc. (PFE)–NYSE *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued,.
The sector did OK during the pricing hearing but it was more of a mixed bag than across the board out- or under-performance. Today everything is down, so it is.
We already discussed what an option is, and how it can help with risk management. When I was talking about risk management, I was talking about how options require a.
Today is going to be an interesting day. Yes, there is the drug pricing testimony in Congress and that is simply a show and grandstanding that has no impact on.
GW Pharmaceuticals made the mistake of allowing expectations to exceed its abilities, forcing the company to announce a delay in the read-out of its pivotal Dravet study. Data originally anticipated for release.
In the last article, I discussed the basics of options. What they are, their classification, properties, and the different types that exist. I also mentioned how options allow you.
Gilead Sciences Inc. (GILD) –Nasdaq GILD dropping hard after MRK receive the FDA approval for a less expensive alternative to Gilead’s hepatitis C drug and pricing it with.
It was obviously another bad day for the sector. The technicals look broken. The headlines are all about pricing. Buyers are on strike. There are no real exciting near term.
The sector finally caught a break with the macro headwinds seeming to pause only to get sector specific headwinds with Donald Trump talking about drug pricing. It was not clear.
This was originally going to be titled “Ahead of the AdCom” but that no longers seems fitting. The highly anticipated Advisory Committee meeting originally scheduled for Friday January 22 was.
It is a mixed start to the week but at least we have some biotech news to talk about even if it is not exactly what was expected. That being.
SPDR S&P Biotech ETF (XBI)–NYSE We will maintain our focus on the XBI as the biotech barometer, many are waiting for the XBI to outperform the IBB again.
The market seems to be catching its footing but again if we are bottoming we are in the early stages and confirmation still needs to happen but I am cautiously.
Not much news as most people wait on SRPT questions as the panel approaches but even then there will not be a lot of new information in the questions (yes,.
I hope everyone enjoyed the move yesterday as it looks like it was only a quick respite to the relentless decline in 2016. Sentiment will eventually change but the hopes.
The year is off to an even worst start as all the secondaries are getting bad prices (to varying degrees of bad) and all are breaking those prices. China continues.
While the market recovered a little into the end of the day yesterday and had a slight positive bias this morning, it is still not looking too healthy. I am.
I figured there would be a more positive bias as we headed into the end of the year but the market has seen some selling. Obviously volume is low but.
I am back and ready to get into the sector again. Some news since I have been gone but for this week I mainly want to focus on 2016 previews.